|
Association of neuroendocrine (NE) mRNA expression profiling in hormone-sensitive tumors samples with adverse clinical outcome in castration-resistant prostate cancer (CRPC) patients. |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Sanofi |
|
|
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Ipsen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Janssen; Roche; Sanofi |
Research Funding - Astellas Pharma; AstraZeneca; Pierre Fabre |
Travel, Accommodations, Expenses - Astellas Amgen BioPharama; AstraZeneca; Roche |
|
|
Consulting or Advisory Role - Sanofi |
Speakers' Bureau - Bristol-Myers Squibb; Pfizer |
Travel, Accommodations, Expenses - Lilly; Sanofi |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen; MSD; Pfizer; Roche |
Speakers' Bureau - Astellas Amgen BioPharama; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche; Sanofi |
Research Funding - MSD; Pfizer; Takeda |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Johnson & Johnson; MSD Oncology; Pfizer; Roche; Sanofi |
Speakers' Bureau - Asofarma; Astellas Pharma; Bayer; Johnson & Johnson |
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Arog (Inst); Astellas Pharma (Inst); AVEO (Inst); Bayer (Inst); Blueprint Medicines (Inst); BN ImmunoTherapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Cougar Biotechnology (Inst); Deciphera (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); Leurquin Mediolanum (Inst); Lilly (Inst); Medimmune (Inst); Millennium (Inst); Nanobiotix (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi/Aventis (Inst); SFJ Pharmaceuticals Group (Inst); Teva (Inst) |
Travel, Accommodations, Expenses - AstraZéneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Amgen BioPharama; Bristol-Myers Squibb; Ipsen; Pfizer |
Travel, Accommodations, Expenses - Astellas Amgen BioPharama; Bristol-Myers Squibb; Ipsen; Pfizer |
|
Leonardo Rodriguez-Carunchio |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Novartis (I) |
Honoraria - Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; NanoString Technologies (Inst); Novartis; Pfizer; Roche |
Research Funding - Novartis (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY |
Travel, Accommodations, Expenses - Daiichi Sankyo |
Other Relationship - Oncolytics |
|
|
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Amgen (I); Astellas Pharma; AstraZeneca; Bayer; Janssen; Pfizer; Pfizer; PFIZER (I); Roche; Roche (I) |
Research Funding - Bayer; Janssen; Roche |
Travel, Accommodations, Expenses - Janssen-Cilag; Roche (I) |